Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

664
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
664
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

517
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
517
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Competencies for Clinical Leadership in Oncology: A Framework for Cancer Department Governance.

JCO oncology practice·2026
Same author

Interleukin-8 and extracellular vesicles spread senescence in Lymphangioleiomyomatosis microenvironment.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Robot-assisted thoracoscopic diaphragmatic plication with absorbable mesh application: surgical technique.

Journal of visualized surgery·2026
Same author

The Dual Faces of Gestational Diabetes Mellitus: Maternal and Placental Origins.

American journal of perinatology·2026
Same author

Post-operative outcomes of lung resection after perioperative chemoimmunotherapy for stage IIB-IIIB non-small-cell lung cancer in the elderly: a single center real-life experience.

Journal of thoracic disease·2026
Same author

Author response In response to: JOPP-26-0271 The French Society for Oncology Pharmacy commentary on Iannopollo M., J Oncol Pharm Pract, 2026.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Related Experiment Video

Updated: Sep 16, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.3K

Adjuvant Immunotherapy for Resectable Non-Small Cell Lung Cancer: Current Advances and Future Perspectives.

Alice Ravasin1, Lavinia Gatteschi1, Valentina Massa2

  • 1Thoracic Surgery Unit, Careggi University Hospital, 50134 Florence, Italy.

Cancers
|July 12, 2025
PubMed
Summary

Immune checkpoint inhibitors (ICIs) significantly improve disease-free survival for resectable non-small cell lung cancer (NSCLC) after surgery. Ongoing research focuses on optimizing patient selection and treatment duration for better long-term outcomes.

Keywords:
adjuvant chemotherapyadjuvant immunotherapyimmune-checkpoint inhibitorsresectable non-small cell lung cancer

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Related Experiment Videos

Last Updated: Sep 16, 2025

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.3K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Adjuvant treatment for resectable non-small cell lung cancer (NSCLC) has evolved with the advent of immune checkpoint inhibitors (ICIs).
  • ICIs enhance the host immune system to target cancer cells, improving outcomes in various malignancies.
  • Recent clinical trials have highlighted the efficacy of ICIs in the adjuvant setting for NSCLC.

Purpose of the Study:

  • To review the current evidence on the efficacy and safety of ICIs in adjuvant treatment for resectable NSCLC.
  • To discuss the role of biomarkers, such as Programmed Death-Ligand 1 (PD-L1), in patient selection.
  • To explore ongoing research into optimizing treatment duration and combination therapies.

Main Methods:

  • Review of key clinical trials, including IMpower010 (atezolizumab) and PEARLS/KEYNOTE-091 (pembrolizumab).
  • Analysis of disease-free survival (DFS) data based on PD-L1 expression and disease stage.
  • Evaluation of safety profiles and immune-related adverse events associated with ICIs.

Main Results:

  • Adjuvant ICIs demonstrated significant improvements in DFS for resectable NSCLC across different stages and PD-L1 expression levels.
  • Atezolizumab showed a DFS benefit in stage II-IIIA NSCLC with PD-L1 expression ≥1% (HR 0.66) and the overall population (HR 0.79).
  • Pembrolizumab improved DFS in stage IB-IIIA NSCLC compared to placebo, with median DFS of 53.6 months versus 42.0 months.

Conclusions:

  • ICIs represent a significant advancement in adjuvant therapy for resectable NSCLC, improving DFS.
  • Further research is needed to refine patient selection through biomarkers and optimize treatment strategies.
  • Careful monitoring for immune-related adverse events is crucial, especially in combination regimens.